News tagged with atorvastatin
Study finds statin costs 400 percent higher in US compared to UK
In the United States, the cost paid for statins (drugs to lower cholesterol) in people under the age of 65 who have private insurance is approximately 400 percent higher than comparable costs paid by the government in the ...
Medications
Jan 05, 2012 |
3.7 / 5 (3) |
12
Statins reduce deaths from infection and respiratory illness, eight years on from trial
The death rate among patients prescribed a statin in a major trial that ended in 2003 is still lower than those given a placebo, even though most participants in both groups have been taking statins ever since. ASCOT, the ...
Cardiology
Aug 28, 2011 |
5 / 5 (2) |
0
Two statin drugs similarly effective in reversing coronary heart disease
Maximum doses of Crestor (rosuvastatin) or Lipitor (atorvastatin) are similarly effective in reversing the buildup of cholesterol plaques in the coronary artery walls (atherosclerosis) after 24 months of treatment, according ...
Cardiology
Nov 15, 2011 |
3 / 5 (2) |
2
Type 2 diabetes linked to higher risk of stroke and CV problems; metabolic syndrome isn't
Among patients who have had an ischemic stroke or transient ischemic attack (TIA), type 2 diabetes was associated with an increased risk of recurrent stroke or cardiovascular events, but metabolic syndrome was not, according ...
Neuroscience
Jun 13, 2011 |
5 / 5 (1) |
0
US approves India's Ranbaxy to make generic Lipitor
Indian pharmaceutical giant Ranbaxy won US regulatory approval to make the first generic version of cholesterol lowering drug Lipitor, a Pfizer product whose patent expired Wednesday.
Medications
Dec 01, 2011 |
5 / 5 (1) |
0
Greater drop in LDL seen with atorvastatin plus PCSK9 antibody
(HealthDay)—Addition of the fully human serum proprotein convertase subtilisin/kexin 9 monoclonal antibody, SAR236553, to atorvastatin is associated with greater reductions in low-density lipoprotein (LDL) ...
Medical research
Nov 02, 2012 |
5 / 5 (1) |
0
High potency statins pose significantly higher risk of kidney injury than low potency, say experts
Patients taking high potency statins for high blood pressure are at a 34% higher risk of being hospitalised for acute kidney injury (AKI), compared with those taking low potency statins, a paper published today in BMJ sugges ...
Cardiology
Mar 19, 2013 |
5 / 5 (1) |
1
Statin alternative looks promising in early trials
(HealthDay) -- Administration of REGN727, a monoclonal antibody to proprotein convertase subtilisin/kexin 9 (PCSK9), significantly reduces low-density lipoprotein (LDL) cholesterol levels, according to the ...
Cardiology
Mar 22, 2012 |
3 / 5 (1) |
1
|
Different drug combinations work best for prevention versus treatment of colorectal tumors
Colorectal cancer is the second leading cause of cancer-related deaths in the United States. Once colorectal cancer has spread to other parts of the body, only 11 percent of patients will survive five years from the date ...
Cancer
Apr 07, 2013 |
1 / 5 (1) |
0
Atorvastatin
Atorvastatin (INN) ( /əˌtɔrvəˈstætən/), sold by Pfizer under the trade name Lipitor, is a member of the drug class known as statins, used for lowering blood cholesterol. It also stabilizes plaque and prevents strokes through anti-inflammatory and other mechanisms. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body.
Atorvastatin was first synthesized in 1985 by Bruce Roth while working at Parke-Davis Warner-Lambert Company (now Pfizer). With 2008 sales of US$12.4 billion, Lipitor was the top-selling branded pharmaceutical in the world. U.S. patent protection was scheduled to expire in June 2011. However, Pfizer made an agreement with Ranbaxy Laboratories to delay the generic launch in the U.S. until November 30, 2011.
For more information about Atorvastatin, read the full article at
Wikipedia.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
